Working on improving the efficacy and safety of antigen-specific immunotherapy for Acute Myeloid Leukemia (AML), including Chimeric Antigen Receptor (CAR)-based therapy at the Walter lab

DPhil student in Mark Howarth's group in the Department of BiochemistryCo-developed the NeissLock protein crosslinking system in Mark Howarth’s group for new modes of therapeutic delivery (UK patent: 2003683.6)Performed biochemical characterization and engineering of the NeissLock system using rational design and directed evolution

Involved in conceptualization of business model for biotech start-up involved in discovery of multispecific antibodies (Patent: WO2022200804A2)Won 2nd prize in Panacea Stars Develop 2020 and participated in YCombinator Winter Batch 2021

Generated stable cell lines for phenotypic screening of libraries for leads that can reactivate mutant p53Investigated rescue of p53 function using single-chain variable fragments (ScFvs) and other specific peptides

Organised Science, Technology, Engineering and Maths (STEM) activities for students from disadvantaged backgrounds to stimulate their interest in science

Worked on project studying MYC oncogenes at Lars-Gunnar Larsson’s lab in Department of Microbiology, Tumour and Cell BiologyUtilised cell culture and immunohistochemistry to study the in vitro and in vivo effects of a new small molecule inhibitor of MYC in 3 different cancer modelsParticipated in the poster presentation at the Amgen Scholars’ Europe Program Symposium atCambridge